Across all study participants, 34.4% of those treated with FB102 reached FVASI50 and 12.5% attained FVASI75 at week 24.

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) was featured in a recent article that discussed its advancement of its ...

Cognito Therapeutics, a clinical-stage neurotechnology company developing novel therapies for neurodegenerative disorders, ...

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) was featured in a recent article that discussed ...

Detailed price information for Forte Biosciences Inc (FBRX-Q) from The Globe and Mail including charting and trades.

FMP374 is a dual-acting NMDA modulator aiming to overcome challenges with older NMDA antagonists. In preclinical TRD models, ...

Elevara Medicines Appoints Biotech Veteran as CEO Founder and former CEO of Nasdaq listed IO Biotech, Dr Mai-Britt Zocca ...

Draig Therapeutics, a clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric ...

Key Points Interested in Veradermics, Incorporated? Here are five stocks we like better. Veradermics reported a strong phase ...

Fi 7 validation with high-density signal distribution, enhanced spatial resolution, and compact RF system integration.

( (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled ...

FDA Drug Approvals and Regulatory Updates Drug Pharmacologic class Indication More information Cardiovascular Disease Tryngolza (olezarsen) Apolipoprotein C-III-directed antisense oligonucleotide ...